Moody Aldrich Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Moody Aldrich Partners’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.04M	Buy	+57,802	New	+$894K	0.19%	120
2023 Q1	–	Sell	-38,064	Closed	-$1.41M	–	157
2022 Q4	$1.41M	Buy	+38,064	New	+$1.35M	0.29%	103

Other funds holding AMLX

PSP Research Newtown Square, Pennsylvania $188M AUM

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SIC

Salem Investment Counselors Winston Salem, North Carolina $4.03B AUM 61.49% 1-Year Est. Return

Moody Aldrich Partners's AMLX Position: Q2 2026 in Review

Moody Aldrich Partners opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 57,802 shares worth $1.04M. The stake represents 0.19% of the portfolio and ranks #120 among its holdings. This is a return to the name: Moody Aldrich Partners previously reported a position in AMLX as recently as Q4 2022.

Moody Aldrich Partners first reported a position in AMLX in Q4 2022 and has held it in 2 quarters since. The position peaked at $1.41M in Q4 2022. 8 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Moody Aldrich Partners held 57,802 shares of Amylyx Pharmaceuticals worth $1.04M as of Q2 2026.
Amylyx Pharmaceuticals was a new Moody Aldrich Partners position in Q2 2026.
Amylyx Pharmaceuticals made up 0.19% of Moody Aldrich Partners's portfolio in Q2 2026, its #120 holding.
Moody Aldrich Partners first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 2 quarters since.
Moody Aldrich Partners's Amylyx Pharmaceuticals position peaked at $1.41M in Q4 2022.
8 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.